Adicet Bio, Inc. 8-K

What Happened Adicet Bio, Inc. (ACET) filed an 8‑K on June 18, 2026 reporting the results of its June 17, 2026 Annual Meeting of Stockholders. Shareholders elected three Class II directors—Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger—for three‑year terms ending in 2029, approved a non‑binding advisory vote on the compensation of the company’s named executive officers, and ratified KPMG LLP as the company’s independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Director elections (three‑year terms through 2029):
  • Jeffrey Chodakewitz: For 4,629,969; Withheld 732,047; Broker non‑votes 1,384,153
  • Steve Dubin: For 4,596,116; Withheld 765,900; Broker non‑votes 1,384,153
  • Michael Grissinger: For 5,257,041; Withheld 104,975; Broker non‑votes 1,384,153
• Advisory vote on executive compensation: For 4,611,540; Against 745,537; Abstain 4,939; Broker non‑votes 1,384,153 (non‑binding)
• Auditor ratification: KPMG LLP ratified as independent registered public accounting firm for year ending December 31, 2026 — For 6,719,352; Against 25,206; Abstain 1,611
• No other matters were voted on at the Annual Meeting. The 8‑K was signed by CFO Nick Harvey on June 18, 2026.

Why It Matters These votes confirm the company's governance and oversight team for the next three years and show shareholder support for current executive pay policies on an advisory basis. Ratifying KPMG maintains continuity for the company’s external audit for 2026. For investors, these outcomes affect board composition, governance continuity, and oversight of financial reporting, but do not themselves change operations or financial results.